Ignite Creation Date:
2025-12-24 @ 7:02 PM
Ignite Modification Date:
2025-12-28 @ 1:06 AM
Study NCT ID:
NCT06770257
Status:
WITHDRAWN
Last Update Posted:
2025-06-03
First Post:
2025-01-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy
Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12-10
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-12-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06-10
Completion Date Type:
ESTIMATED
First Submit Date:
2025-01-07
First Submit QC Date:
None
Study First Post Date:
2025-01-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-28
Last Update Post Date:
2025-06-03
Last Update Post Date Type:
ACTUAL